MX2024006925A - Polipeptidos de il-18 estabilizados y usos de estos. - Google Patents

Polipeptidos de il-18 estabilizados y usos de estos.

Info

Publication number
MX2024006925A
MX2024006925A MX2024006925A MX2024006925A MX2024006925A MX 2024006925 A MX2024006925 A MX 2024006925A MX 2024006925 A MX2024006925 A MX 2024006925A MX 2024006925 A MX2024006925 A MX 2024006925A MX 2024006925 A MX2024006925 A MX 2024006925A
Authority
MX
Mexico
Prior art keywords
polypeptides
stabilized
making
methods
same
Prior art date
Application number
MX2024006925A
Other languages
English (en)
Inventor
Travis William Bainbridge
Baykara Beyza Bulutoglu
Jonathan Thomas Sockolosky
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2024006925A publication Critical patent/MX2024006925A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona polipéptidos de IL-18 estabilizados y métodos para su elaboración y uso.
MX2024006925A 2021-12-15 2022-12-14 Polipeptidos de il-18 estabilizados y usos de estos. MX2024006925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163289948P 2021-12-15 2021-12-15
PCT/US2022/081529 WO2023114829A1 (en) 2021-12-15 2022-12-14 Stabilized il-18 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2024006925A true MX2024006925A (es) 2024-06-20

Family

ID=85173149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006925A MX2024006925A (es) 2021-12-15 2022-12-14 Polipeptidos de il-18 estabilizados y usos de estos.

Country Status (9)

Country Link
EP (1) EP4448558A1 (es)
KR (1) KR20240122448A (es)
CN (1) CN118401546A (es)
AU (1) AU2022414067A1 (es)
CA (1) CA3237618A1 (es)
IL (1) IL313169A (es)
MX (1) MX2024006925A (es)
TW (1) TW202330582A (es)
WO (1) WO2023114829A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
WO2001007611A2 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
MX360352B (es) 2012-02-15 2018-10-30 Hoffmann La Roche Cromatografia de afinidad basada en receptores fc.
BR112015027385A2 (pt) 2013-04-29 2017-08-29 Hoffmann La Roche Anticorpos modificados de ligação ao fcrn humano e métodos de uso
IL272635B2 (en) * 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
EP4293039A1 (en) * 2021-02-10 2023-12-20 Nagasaki University Novel human interleukin-18 variant and use therefor
WO2023010021A1 (en) * 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins

Also Published As

Publication number Publication date
AU2022414067A1 (en) 2024-05-23
CN118401546A (zh) 2024-07-26
IL313169A (en) 2024-07-01
EP4448558A1 (en) 2024-10-23
TW202330582A (zh) 2023-08-01
KR20240122448A (ko) 2024-08-12
CA3237618A1 (en) 2023-06-22
WO2023114829A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
WO2020084305A9 (en) Bicyclic peptide ligands and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019008348A (es) Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
MX2022005091A (es) Metodos de preparacion de una muestra enriquecida para la secuenciacion de polipeptidos.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2020013722A (es) Anticuerpos que comprenden polipeptido insertado en la region de marco 3.
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2022003825A (es) Organismos semisinteticos eucariotas.
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2023014154A (es) Anticuerpos anti-ccr8.
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
MX2021008005A (es) Bibliotecas de peptidos y metodos de uso de las mismas.
MX2024006925A (es) Polipeptidos de il-18 estabilizados y usos de estos.
MX2022014899A (es) Variantes y composiciones del lfa3 y sus usos.
MX2022011752A (es) Agentes de fijacion a tie2 y metodos de uso.